4D Molecular Therapeutics (FDMT) Expected to Post Quarterly Earnings on Monday

4D Molecular Therapeutics (NASDAQ:FDMT) is projected to release its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect 4D Molecular Therapeutics to post earnings of ($1.04) per share and revenue of $3.62 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The firm had revenue of $3.05 million during the quarter, compared to analyst estimates of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. On average, analysts expect 4D Molecular Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

4D Molecular Therapeutics Trading Down 3.3%

4D Molecular Therapeutics stock opened at $9.84 on Monday. 4D Molecular Therapeutics has a 52 week low of $5.11 and a 52 week high of $14.00. The stock has a market cap of $514.60 million, a price-to-earnings ratio of -3.87 and a beta of 2.70. The company’s 50-day moving average price is $10.58 and its two-hundred day moving average price is $9.66.

Wall Street Analyst Weigh In

Several research firms have weighed in on FDMT. B. Riley Financial began coverage on 4D Molecular Therapeutics in a research note on Friday. They set a “buy” rating and a $37.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. The Goldman Sachs Group set a $33.00 target price on 4D Molecular Therapeutics in a report on Friday, May 8th. Chardan Capital upgraded shares of 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Finally, Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $30.67.

Insider Buying and Selling at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider David Kirn sold 114,746 shares of the stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the transaction, the insider directly owned 942,485 shares of the company’s stock, valued at $9,867,817.95. This represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Scott Bizily sold 9,810 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the sale, the insider directly owned 8,617 shares of the company’s stock, valued at $103,404. The trade was a 53.24% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 184,811 shares of company stock worth $2,075,906. 7.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd acquired a new position in 4D Molecular Therapeutics in the first quarter valued at about $39,000. Wexford Capital LP bought a new position in shares of 4D Molecular Therapeutics in the 3rd quarter valued at about $41,000. AQR Capital Management LLC acquired a new stake in 4D Molecular Therapeutics during the 1st quarter worth $46,000. Rangeley Capital LLC acquired a new position in shares of 4D Molecular Therapeutics in the 2nd quarter valued at $48,000. Finally, Daiwa Securities Group Inc. lifted its stake in 4D Molecular Therapeutics by 3,362.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after buying an additional 6,186 shares during the period. Institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.